Have you ever heard of Occam's Razor?
The principle is: Among competing hypotheses, the one with the fewest assumptions should be selected., i.e. the simplest theory (that fits the facts) is usually the correct one.
So, I'm sticking with simple incompetence and/or lack of motivation as an explanation for what has happened here (vs. elaborate planning involving Machiavellian motives).
Although sabotage (from a whistleblower) may have played a part, now Carter (and REVO shareholders) are in a much worse position, with management having to do a huge amount of work (refiling years of audited financials as well as filing form 211) just to get back to square one.
Given the considerable amount of work involved in the financials and the 211, and the glacial speed at which they have moved in the past, I imagine that it might actually take them six months to a year to get REVO reinstated with the SEC as an OTC pink upgrade.
I agree with you that considering the patents and the incredible potential here, it's hard to conceive of this level of incompetence or to wrap your head around what has happened so far.